Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

This study is testing whether adding an immunotherapy drug (tislelizumab) to a short targeted course of radiation therapy (stereotactic radiotherapy) can help treat patients with later-stage non-squamous non-small cell lung cancer (NSCLC) who have not had any prior treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with Stage IIIB, IIIC, or IV non-squamous non-small cell lung cancer, confirmed by biopsy - You have not received any prior systemic treatment for this cancer - Your overall health is adequate for treatment (ECOG 0 to 2) **You may NOT be eligible if...** - Your tumor has known driver gene mutations such as EGFR, ALK, BRAF, or ROS1, which require different targeted therapies - You have active or unstable autoimmune disease - You have had serious heart, lung, or other organ complications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.